Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
103 hedge funds and large institutions have $176M invested in Antares Pharma, Inc. in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 14 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding
Funds holding: 103 → 103 (0)
6% less call options, than puts
Call options by funds: $333K | Put options by funds: $356K
5% less capital invested
Capital invested by funds: $185M → $176M (-$9.32M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.99M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.88M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.24M |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$1.1M |
| 5 |
Two Sigma Investments
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$8.84M |
| 2 |
BC
Broadfin Capital
New York
|
-$4.93M |
| 3 |
AC
Armistice Capital
New York
|
-$4.63M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$3.05M |
| 5 |
Renaissance Technologies
New York
|
-$2.09M |
ATRS Hedge Fund Activity: Q3 2017 in Review
103 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2017, worth a combined $176M — down 5% from $185M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ATRS positions and 14 closed out — a net gain of 1 holder — while 32 added to existing stakes and 28 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $8.99M. The largest seller was Rubric Capital Management (New York), cutting an estimated $8.84M.
- 103 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $176M of Antares Pharma, Inc. stock for Q3 2017, down 5% quarter-over-quarter.
- 15 funds opened new Antares Pharma, Inc. positions in Q3 2017 and 14 closed out, a net change of +1 holder.
- The largest Antares Pharma, Inc. buyer in Q3 2017 was Fidelity Investments, an estimated $8.99M added.
- The largest Antares Pharma, Inc. seller in Q3 2017 was Rubric Capital Management (New York), an estimated $8.84M sold.
Based on aggregated 13F filings for Q3 2017.